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Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) is
a newly defined syndrome encompassing patients with
chronic kidney disease that have a triad of biochemical
alterations in calcium, phosphorus and parathyroid hormone,
vascular calcification, and bone abnormalities. Here we
describe a novel Cy/þ rat model of slowly progressive kidney
disease spontaneously developing the three components of
CKD-MBD when fed a normal phosphorus diet. Since the
renal disorder progressed ‘naturally’ we studied the effect of
dietary manipulation during the course of the disease.
Animals with early, but established, chronic kidney disease
were fed a casein-based or a grain-based protein diet both of
which had equivalent total phosphorus contents. The two
different sources of dietary protein had profound effects on
the progression of CKD-MBD, likely due to differences in
intestinal bioavailability of phosphorus. Although both
dietary treatments resulted in the same serum phosphorous
levels, the casein-fed animals had increased urinary
phosphorus excretion and elevated serum FGF23 compared
to the grain-fed rats. This model should help identify early
changes in the course of chronic kidney disease that may
lead to CKD-MBD.
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Vascular calcification is common in patients with chronic
kidney disease (CKD), appearing in 30–65% of patients with
stages 3–5 CKD and 50–80% of patients with stage 5D CKD,
and is associated with increased morbidity and mortality.1–3
In the coronary arteries, this calcification is typically intimal,
within atherosclerotic plaques or as circumferential intimal
lesions, whereas in the aorta, calcification occurs in both the
intimal and medial layers of the vessel wall (atherosclerosis
and Mo¨nkeberg’s medial calcific sclerosis). The pathogenesis
of vascular calcification is complex, but in vitro studies
support the concept of an initial transformation of vascular
smooth muscle cells to chondrocyte/osteoblast-like cells in
response to hyperphosphatemia, uremia, inflammation, and
elevated glucose levels.4 These transformed cells then lay
down a matrix of collagen and non-collagenous proteins and
produce matrix vesicles that serve as the initial nidus for
calcification, similar to the process of normal bone miner-
alization. This process is accelerated in the clinical setting of
CKD, possibly because of hyperphosphatemia and hyperpar-
athyroidism, the use of high dose calcium salts as phosphate
binders that increase the overall calcium load, abnormal bone
remodeling, and relative deficiencies of circulating and locally
produced inhibitors of calcification. This interrelationship of
vascular calcification with abnormal serum biochemistries
and abnormal bone remodeling is the basis for the recently
named syndrome, chronic kidney disease-mineral bone
disorder (CKD-MBD).5 The complexity of this interrelation-
ship makes studies in humans difficult, as one cannot easily
control one variable without impacting another. Thus, there
is a clear need for an appropriate animal model in which to
understand the progressive pathophysiology of CKD-MBD,
as well as to test interventions.
Several animal models of vascular calcification exist,
including the adenine nephrotoxic model6,7 and the 5/6th
nephrectomy models in rats.8,9 In both models, animals
develop severe hyperphosphatemia and hyperparathyroidism
due to an acute kidney injury, which is followed by CKD.
These models have provided useful information on the
pathophysiology of vascular calcification. However, they
represent advanced CKD, due to the severity of acute injury,
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with creatinine clearances that approximate late 4 or 5 stage
human CKD. In both disease states, diet is an important
factor. The 5/6th nephrectomy rat model is generally fed a
high-phosphorus diet to induce hyperphosphatemia.8,9 The
adenine model has a more rapid onset and severe course of
kidney disease as well as hyperparathyroidism and arterial
calcification than the 5/6th nephrectomy model. Curiously,
the adenine model develops more consistent arterial
calcification on a low-protein diet.7 The type of calcium
deposition may also differ in these models.10 In mice,
spontaneous calcification in the setting of surgically induced
acute kidney injury followed by CKD, is not found unless
there is a concomitant genetic abnormality that is proathero-
genic, such as ablation of the low-density lipoprotein
receptor or the ApoE genes.11,12 Although useful, none of
these rodent models provide the opportunity to study a
slowly progressive CKD, nor earlier stages of CKD-MBD.
This is important because studies demonstrate that patients
in earlier stages of CKD also have coronary artery calcifica-
tion1,13,14 suggesting that the process begins before beginning
dialysis. Therefore, there is a clear need for additional animal
models to provide the opportunity to study slowly progres-
sive CKD to better understand the triad of CKD-MBD: (1)
abnormal serum biochemistries, (2) abnormal bone remo-
deling, and (3) vascular calcification. In this report, we
describe a novel model of progressive CKD-MBD, the Cy/þ
rat, and demonstrate its usefulness for evaluating early
pathogenesis and the impact of different dietary regimens on
the course of CKD-MBD.
RESULTS
Main study assessment of CKD
To assess the magnitude of uremia, we compared blood urea
nitrogen (BUN), creatinine, weight, and hematocrit in the
38-week Cy/þ CKD animals each treated for 18 weeks with
the casein protein-based diet with either 0.7% (normal) or
0.2% phosphorus (low), comparing these CKD animals to
normal littermates. The 38-week animals with CKD had
elevated BUN at 20 weeks, which persisted (Figure 1a). The
animals in the CKD groups also had elevated serum
creatinine values (normal, 0.62±0.01 mg/100 ml; CKD/
0.7% Pi, 3.05±0.27 mg/100 ml; CKD/0.2% Pi, 1.93±0.25
mg/100 ml; Po0.01). The low-phosphorus diet attenuated
the progressive CKD as assessed by BUN (Figure 1a). In the
38-week end-point groups, the CKD animals in both
treatment groups weighed less than normal littermate
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Figure 1 | Biochemical changes over time. Cy/þ rats were placed on the study diet at 20 weeks of age. The 38-week-old animals had an
intermediate blood draw at 34 weeks for phosphorus, parathyroid hormone, and calcium for a total of three time points, whereas BUN was
measured at 20 and 38 weeks. The graphs show changes in plasma levels over time for BUN (a), phosphorus (b), intact parathyroid hormone
(c), and calcium (d). The data demonstrate that CKD animals fed a 0.7% phosphorus diet had progression of CKD as assessed by BUN,
hyperphosphatemia, and hyperparathyroidism compared to the normal littermates. Feeding a low-phosphorus diet (0.2%) ameliorated
these changes. As detailed in the text, these changes over time were significant (Po0.001), even when adjusted for baseline values and final
BUN. At 38 weeks, the calcium levels were greater in the CKD/0.2% Pi animals than in the CKD/0.7% Pi fed animals (P¼ 0.04). n¼ 15–17 per
group. *Po0.05 compared to normal animals, þPo0.05 0.2% phosphorus-treated CKD animals versus 0.7% phosphorus-treated CKD
animals.
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animals (at week 38: normal, 588±9 g; CKD/0.7% Pi,
471±17 g; CKD/0.2% Pi, 537±8 g; Po0.01, between normal
and both CKD groups). Lastly, animals in the two CKD
treatment groups were anemic by 38 weeks, with more severe
anemia occurring in the animals on the normal (0.7%)
phosphorus diet (hematocrit in week-38 end-point animals:
normal, 0.50±0.00%; CKD/0.7% Pi, 0.29±0.01%; CKD/
0.2% Pi, 0.36±0.02%; Po0.01, between each of the groups).
The CKD animals in the 38-week end-point groups were
sicklier, particularly those with severe hyperparathyroidism/
hyperphosphatemia in Group 2 (CKD/0.7% phosphorus
diet). Of the 43 animals in the CKD/0.7% phosphorus diet
group, 18 either died (n¼ 11) or became morbidly ill
requiring euthanasia (n¼ 7), whereas only 1 of 31 normal
animals died, and 3 of 29 animals in the CKD/0.2% Pi group
died. Thus, by all indices (BUN, creatinine, body weight,
hematocrit), the Cy/þ animals on both the normal (0.7%
phosphorus) and low (0.2% phosphorus) diets had worse
kidney disease when compared to the normal littermates, but
the low-phosphorus diet attenuated these abnormalities and
prevented early morbidity and mortality.
Main study assessment of CKD-MBD
Biochemical parameters. To assess the biochemical para-
meters of CKD-MBD, plasma parathyroid hormone (PTH),
phosphorus, and calcium were assessed at the start of
treatment (20 weeks), at 34 weeks, and again at 38 weeks
(killing). The CKD animals fed with the normal 0.7%
phosphorus diet developed progressive hyperphosphatemia
and hyperparathyroidism. Figure 1b–d demonstrates the
change over time for these measures in the 38-week animals.
These differences in end-point measurements for phosphorus
(P¼ 0.03) and PTH (P¼ 0.006) remained significant even if
adjusted for baseline values of phosphorus or PTH
(respectively), baseline BUN, end-point BUN, or change in
BUN using a mixed model, suggesting that the observed
differences were not solely due to changes in kidney function
and that the premature death did not alter our findings. In
fact, the excessive animal deaths in the normal-phosphorus
diet group would have increased the observed differences. In
contrast, the serum calcium was slightly increased only in the
38-week CKD/0.2% phosphorus-treated animals compared
to the CKD/0.7% Pi-treated animals (P¼ 0.04 when adjusted
for baseline calcium and BUN; Figure 1d). In the second
group of animals, killed at 34 weeks, biochemical assessments
were made at baseline (week 20), mid point (week 29), and
end point (week 34). Similar to the 38-week treatment group,
the 34-week animals had progressive hyperphosphatemia and
hyperparathyroidism (Table 1).
Vascular calcification. To determine the extent and
magnitude of arterial calcification, the calcium content of
the thoracic aorta was examined by quantitative biochemistry
and semiquantitative histology. The thoracic aorta was more
calcified in the CKD animals treated with the normal (0.7%
phosphorus) diet than either the normal animals or the CKD
animals treated with the low (0.2%) phosphorus diet (Figures
2, 3a and b), but calcification was quantifiable at levels above
normal animals only at 38 weeks. The magnitude of the
calcification correlated with the phosphorus level (r¼ 0.67,
Po0.001), but not PTH or calcium. Histologic evaluation of
the 38-week animals at identical levels of the upper thoracic
aorta revealed that 60% (6 of 10) of the CKD/0.7%
phosphorus-treated animals had significant medial calcifica-
tion (3 animals with 3þ calcification, 2 animals with 2þ
calcification, and 1 animal with 1þ calcification). In
contrast, none of the normal animals or CKD/0.2%
phosphorus-treated animals had calcification. No histologic
evidence of calcification was observed at 34 weeks. Scanning
electron microscopy with energy dispersive X-ray micro-
analysis demonstrated that the mineral deposits were
composed of calcium, phosphorus, and oxygen indicative
of brushite or hydroxyapatite (Figure 3e).
Bone abnormalities. Static histomorphometry was per-
formed in the CKD animals treated with normal (0.7%) and
Table 1 | Biochemical findings in 34-week animals
N=12–17 Group Baseline (week 20) Week 29 Week 34
BUN (mg/100 ml) Normal 20.9±0.5 ND 15.8±1.2
CKD/0.7% Pi 47.0±1.1 ND 106.7±13.5*
CKD/0.2% Pi 47.8±1.3 ND 52.7±3.9
Phosphorus (mg/100 ml) Normal 6.9±0.1 6.5±0.2 6.1±0.4
CKD/0.7% Pi 7.4±0.2 8.5±0.3 11.6±1.0*
CKD/0.2% Pi 7.5±0.1 6.4±0.2 8.0±0.9
Calcium (mg/100 ml) Normal 10.9±0.3 11.9±0.4 11.0±0.6
CKD/0.7% Pi 11.1±0.4 11.6±0.5 9.8+0.3
CKD/0.2% Pi 11.9±0.2 10.5±0.3 11.8±1.0
PTH (pg/ml) Normal 91±14 98±10 177±52
CKD/0.7% Pi 218±73 1351±246* 3543±648*
CKD/0.2% Pi 114±18 110±14 560±163*
Weight (g) Normal 487±7 560±10 585±12*
CKD/0.7% Pi 481±5 535±6 535±11*
CKD/0.2% Pi 483±6 510±9 519±10*
BUN, blood urea nitrogen; CKD, chronic kidney disease; ND, not done; PTH, parathyroid hormone.
Mean±s.e.m.,
*Po0.05 for difference from baseline.
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low (0.2%) phosphorus diets in the 34-week and 38-week
animals and compared to the normal animals in each time
group. The bone changes in the CKD animals were indicative
of secondary hyperparathyroidism (Table 2; Figure 3c and d:
increased fibrosis, osteoblasts, and osteoclasts) in the CKD
animals treated with the 0.7% phosphorus diet, and a
mineralization defect (increased osteoid volumes and osteoid
surface) in the animals treated with 0.2% phosphorus diet.
The bone volume and trabecular thickness were not different
between the two groups, but the trabecular number was
higher and the trabecular separation lower in the CKD
animals treated with 0.7% phosphorus, consistent with
excessive and uncontrolled hyperparathyroidism (Table 1).
The differences from 34 to 38 weeks reflected continued
progression of severe secondary hyperparathyroidism in the
Cy/þ animals treated with the 0.7% phosphorus diet, and
stabilization or slight improvement of the mineralization
defect in the 0.2% phosphorus-treated animals.
Thus, the Cy/þ animal model spontaneously reflects all
three components of CKD-MBD: biochemical abnormalities,
vascular calcification, and bone abnormalities. The biochem-
ical and bone abnormalities show a progressive change over
time, whereas the vascular calcification was only apparent in
the older animals, perhaps due to more severe hyperpho-
sphatemia and hyperparathyroidism.
Diet study
We previously noted (unpublished observations) that when
our male Cy/þ CKD animals were treated with standard rat
chow, in which protein content was not casein based, the
magnitude of hyperparathyroidism was not as severe as with
a casein-based diet. Therefore, we treated another group of
animals on a grain-based diet. This was a commercially
available diet (Purina 5002) that paralleled the protein and
phosphorus content of the casein diet. Comparing the results
from Cy/þ animals on the two diets (Table 3) demonstrated
a marked difference in magnitude of hyperphosphatemia,
hyperparathyroidism, and severity of CKD compared to the
casein-based, 0.7% phosphorus diet-fed animals (whose
biochemical data is also shown in Figure 1).
Metabolic cage study
To better understand how the protein source could cause
such a marked difference, we conducted 1-week-long
metabolic studies in 20-week-old male Cy/þ CKD rats. At
baseline, before the diet intervention, the BUN levels were
38.0 mg/100 ml±1.4 in the animals on the casein diet, and
42.1 mg/100 ml±1.8 in the animals on the grain diet, which
represents an approximate 50–60% reduction in GFR. After 1
week of diet intervention, there were no differences in serum
phosphorus, calcium, or PTH values between the two groups,
but the fibroblast growth factor 23 (FGF23) levels were higher
in the CKD animals fed with a casein diet versus those fed a
grain diet (Po0.001; Table 4). There was also increased
urinary phosphate excretion in the casein compared to the
grain diet, and an increase in the urine calcium/creatinine
ratio (Table 4). Grain diets typically contain much of the
phosphate source as phytate, which is poorly absorbed from
the gastrointestinal tract. We thus assessed the diets for
phytate content, demonstrating that 60% of the phosphate in
the grain-based diet was in the non-bioavailable phytate
form; whereas the casein diet was devoid of phytate, so all of
the phosphate was bioavailable.
DISCUSSION
In this study, we describe a novel animal model of
spontaneous CKD-MBD. In previous rodent models of
kidney disease, vascular calcification developed only on a
high-phosphorus diet greater than 1%.6,8,15 The advantage of
the Cy/þ rat includes the ability to induce all three
components of CKD-MBD with normal (0.7%) dietary
phosphorus concentration. The biochemical and bone
abnormalities demonstrate a progressive course, whereas
the calcification was only observed late in the disease course.
The aorta vascular calcification was spontaneous and medial
in location, paralleling findings in patients with CKD. Studies
in humans demonstrate that abnormal biochemical changes16
begin when GFR is around 40–50 ml/min (CKD 3–4), whereas
bone17 and vascular calcification disorders1,13,14 are more
prevalent with CKD stages 4–5D. Thus, any effort to prevent
CKD-MBD must first treat the biochemical abnormalities at
this early stage. This Cy/þ rat model develops vascular
calcification at 38 weeks, suggesting the presence of very
severe and/or protracted hyperphosphatemia, and hyperpar-
athyroidism are required to induce arterial calcification.
CKD-MBD with arterial calcification in rodents is a rare
finding. Taken together, this model allows a characterization
of the progressive onset and course of CKD-MBD. This
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Figure 2 | Thoracic aorta calcification. At the time of killing, the
thoracic aorta was removed and its calcium content determined
biochemically. The results demonstrate that there is increased
arterial calcification in the normal (0.7%) phosphorus-treated CKD
animals at 38 weeks, but not at 34 weeks. This implies that
hyperphosphatemia and hyperparathyroidism precede arterial
calcification. Interestingly, the low-phosphorus diet (0.2%),
despite producing modest hyperphosphatemia and
hyperparathyroidism, did not increase calcification in CKD animals
compared to the normal littermates. Solid black bars¼ normal
littermates; open white bars¼CKD (Cy/þ ) animals fed a 0.7%
phosphorus casein-based diet; hatched bars¼CKD animals fed a
0.2% phosphorus casein-based diet. Symbols: *Different than
normal littermates (Po0.03) or low-phosphorus diet, P¼ 0.06
(n¼ 8 per group).
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model also allows us to test interventions early and
chronically to ensure that prevention of CKD-MBD can be
done safely. To our knowledge, this represents the first animal
model of CKD-MBD that occurs spontaneously (no surgery
or drug) on a normal-phosphorus diet.
Our study also demonstrates the importance of diet on
CKD-MBD. Specifically, a low-phosphorus diet can slow or
ameliorate CKD-MBD progression. We also found that
dietary protein source was an important factor. Casein-based
(synthetic) protein sources are often recommended by
laboratory feed manufacturers for experiments because they
can be more easily manipulated to achieve final desired
protein, phosphorus, and calcium concentrations, compared
to grain-based diets. The latter can also be seasonally variable
depending on the available grains. However, grain-based diets
contain most of the phosphate as phytate, which lowers the
bioavailability of this mineral compared to casein sources.
Previous investigators analyzing the effects of various protein
diets found that soy-based diets, compared to casein-based
diets, slowed the progression of cystic kidney disease and
reduced interstitial fibrosis in the Cy/þ rat.18–21 These
investigators hypothesized that this could be due to
differences in insulin-like growth factor-1 or fatty acids, but
they did not investigate the potential role of phosphorus or
parathyroid hormone. Our metabolic studies suggest differ-
ences in bioavailable phosphorus and its impact on the
development of CKD-MBD. However, it is not known
whether the differences in phosphorus could also account
for the observed changes in kidney disease progression
identified by the other authors.18–21 These soy, compared to
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Figure 3 | Histologic evaluation of vascular calcification and bone. (a) A thoracic aorta from a normal (non-CKD) 40-week old animal
stained with MacNeal’s stain demonstrating no calcification. (b) Thoracic aorta from a CKD animal fed with a normal (0.7%) phosphorus diet
demonstrates calcification (in black) in the medial layer with a vascular smooth muscle cell visible within the calcified area. (c, d) Bone from
a CKD animal fed with a normal (0.7%) phosphorus diet demonstrating osteitis fibrosa cystica with osteoclasts (arrowhead), active
osteoblasts (arrows), and in (d), peritrabecular fibrosis (arrow). (e) Scanning electron microscopy with EDS X-ray microanalysis of the aortic
calcifications. Backscatter imaging allowed the identification of the calcification (white region) in the aorta and energy dispersive
spectrometry was used to assess the elemental composition. Compared with the non-calcified region (pink arrow and top spectrum), the
calcified region (green arrow and bottom spectrum) had increased amounts of calcium, oxygen, and phosphorus (compared to carbon and
sodium peaks) indicating a calcium phosphate material such as hydroxyapatite or brushite.
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casein-based diets, have also been found in humans to reduce
albuminuria in non-diabetic nephropathy,22 and would likely
have an impact on overall control of hyperphosphatemia in
patients with CKD. However, our diet studies were
specifically designed to test two diets in which we found
different outcomes in older animals. The diets were not
perfectly matched, but were very comparable for protein,
phosphorus, calcium, and fat content. However, more
research is needed to specifically identify the critical element
or elements in a diet that contributes to the progression of
CKD-MBD, and this model should be useful for these
evaluations.
Another advantage of this animal model is the ability to
study early changes in CKD-MBD. Our metabolic studies,
where younger (20 weeks old) Cy/þ animals were exposed to
different protein sources demonstrated, that despite normal
phosphorus levels, there was an increase in serum FGF23
concentrations with the casein-based diet. FGF23 is secreted
by osteocytes in response to hyperphosphatemia.23 We saw an
elevation in this factor in response to an increased
phosphorus load, even without overt hyperphosphatemia.
However, it is possible that we missed a rise in serum
phosphorus due to the timing of our blood draws.
Interestingly, we did not see a difference in PTH in animals
fed with these two diets. The classic trade-off hypothesis24
suggests that PTH increases early in the course of CKD due to
an inability of the kidney to excrete a phosphorus load. PTH,
in turn, further increases the urinary phosphorus excretion
but at the expense of secondary hyperparathyroidism.
Research in dogs and rats with more advanced CKD clearly
show the importance of PTH,25 but our results suggest that
FGF23 may also be important in early CKD. We may not have
detected an increase in PTH because we studied animals at a
relatively earlier stage of CKD (generally equivalent to human
CKD stage 3), or our blood draw timing failed to detect an
acute rise. However, the urine calcium/creatinine ratio was
higher in the casein- versus grain-treated animals, the
opposite of what one would expect with increased PTH.
Both PTH and FGF23 are phosphaturic hormones, but they
have opposing effects on calcitriol synthesis. Unfortunately,
we did not assess the vitamin D axis in our study. However,
analyzing the interplay of PTH, FGF23, and vitamin D
metabolism during the course of progressive CKD in future
rat and human studies may provide insight into both normal
and abnormal physiology.
In conclusion, we describe a novel rat model of
progressive CKD-MBD that manifests all three components
of CKD-MBD in a manner similar to humans with
progressive CKD. We further demonstrate that the progres-
sion of CKD-MBD and kidney dysfunction itself is affected
by both total phosphorus content and dietary protein type,
and we therefore recommend that protein source be clarified
Table 2 | Static bone histomorphometric parameters in normal and CKD rats
Group 1: normal Group 2: CKD Cy/+ 0.7% Pi diet Group 3: CKD Cy/+ 0.2% Pi diet
Parameter N=5–8 per group 34 weeks 38 weeks 34 weeks 38 weeks 34 weeks 38 weeks
Turnover:
Fibrosis (%) Nonea Nonea 8.5±2.7 4.9±1.8 Nonea Nonea
Ob.S/BS (%) 1.8±0.5a 2.5±0.6a 18.5±3.4 14.9±3.7 10.2±1.5a,b 4.9±1.4a
N.Ob/B.Pm (n/mm) 1.4±0.3a 1.7±0.4a 12.4±2.3 10.1±2.6 7.1±1.0a,b 3.5±0.9a,b
Oc.S/BS (%) 7.6±0.7a 10.3±0.8a 16.5±1.7 22.1±4.5a 23.8±2.3a,b 10.2±1.5a
N.Oc/B.Pm (n/mm) 1.5±0.1a 2.3±0.1a 3.2±0.3 4.1±0.6 4.3±0.3a,b 2.2±0.2a
Mineralization
OV/BV (%) 0.2±0.1 0.29±0.1a 0.9±0.3 1.0±0.3 1.8±0.4b 1.2±0.6
OS/BS (%) 6.3±3.0 4.2±0.8 6.3±3.0 6.4±1.3 14.9±1.8b 9.8±2.4
Volume
BV/TV (%) 11.5±1.4 8.4±0.9 10.8±1.6 10.6±1.3 4.8±1.0 6.9±1.5
Tb.Th (mm) 51.4±2.3a 48.9±2.8 48±3.1a 41.8±2.8 39.0±2.6a,b 40.8±2.7
Tb.Sp (mm) 427±50a 571±44 433±55 405±61 1027±211a 689±107a
Tb.N (n/mm) 2.2±0.2 1.6±0.1a 2.2+0.2 2.5±0.2 1.2±0.2 1.6±0.2a
Cross-sectional area (mm2) 6.8±0.1 6.6±0.1 8.1±0.9a 6.7±0.1 6.1+0.1 6.1±0.2a
Static parameters: BV/TV, trabecular bone volume; Fb.V/TV, intertrabecular fibrosis; Ob.S/BS and Oc.S/BS, osteoblast and osteoclast surface; N.Ob/B.Pm and N.Oc/B.Pm,
osteoblast and osteoclast number per millimeter bone perimeter; OV/BV, osteoid volume; OS/BS, osteoid surface; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation;
Tb.N, trabecular number.
Mean+s.e.m.
aGroup 1 or 3 different from Group 2 at same time point, Po0.05.
bGroup 3 different from Group 1 at same time point, Po0.05.
Table 3 | Effect of dietary protein source in Cy/+ male animals
with CKD
Casein protein source Grain protein source
34 weeks 38 weeks 34 weeks 38 weeks
BUN (mg/100 ml) 107±13.4 140±16.2 62±3.0 86±6.9
Phosphorus (mg/100 ml) 11.6±1.0 14.9±1.5 5.12±0.3 7.2±0.6
Calcium (mg/100 ml) 9.9±0.3 9.8±0.6 8.86±0.3 8.9±0.3
Intact PTH (pg/ml) 3543±648 5151±1067 303±116 421±97
BUN, blood urea nitrogen; PTH, parathyroid hormone.
Mean±s.e.m., casein different than grain in all categories and all time points,
Po0.01.
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in all reports describing experimental animal models.
Lastly, our metabolic studies imply that FGF23 may have a
role in the pathophysiology of CKD-MBD early in the course
of CKD.
MATERIALS AND METHODS
Animal model
We utilized the Cy/þ rat, a Han:SPRD rat with autosomal dominant
polycystic kidney disease.26 The male Cy/þ rat develops a persistent
azotemia, starting at about 10 weeks of age, which progresses to
uremia by about 40 weeks. The renal pathology has been well
characterized with initial cyst development in proximal tubules,
followed by interstitial fibrosis.27 The progressive azotemia is
accompanied by the usual manifestations of CKD, including anemia,
hypertension, and secondary hyperparathyroidism.26 The sponta-
neous genetic mutation (Cy) that leads to cystic kidney disease and
progressive CKD encodes for a protein of unknown function.28 This
rat colony at the Indiana University School of Medicine has been
maintained through successive breeding of heterozygous Cy/þ rats.
This is an autosomal-dominant condition, such that at birth, 1/4 of
the animals are normal (þ /þ), 1/2 are heterozygotes (Cy/þ), and
1/4 are homozygotes (Cy/Cy). Homozygotes (Cy/Cy) of either sex
are easily identified after approximately 10 days of age by abdominal
palpation of enlarged kidneys and elevation in BUN, a finding used
to verify parental heterozygosity. Homozygous Cy/Cy rats develop
massively enlarged kidneys and severe azotemia, and normally die by
4 weeks of age. Heterozygote male animals develop progressive CKD
with a rise in BUN by 10 weeks of age and become markedly uremic
by 40–50 weeks. Heterozygote female animals (and castrated males)
develop progressive CKD with a rise in BUN not detected until 20
weeks of age, followed by uremia at 80 weeks.18,27,29,30 For this study,
male heterozygotes were utilized and all procedures were reviewed
and approved by the Indiana University School of Medicine
Institutional Animal Care and Use Committee.
Main study experimental design
Weaned rats were housed in open top, shoebox cages, and had free
access to tap water and standard chow until they were 20 weeks
old. At that time, animals were separated into three treatment
groups:
Group 1. Normal (þ /þ) littermates fed with a diet containing
18% casein-based protein, 0.7% phosphate, 0.7% calcium, 5% fat
(Harlan Teklan TD.04539) (¼ normal)
Group 2. Cy/þ (cystic/CKD) rats fed with the same diet as
Group 1 (¼CKD/0.7% Pi)
Group 3. Cy/þ (cystic/CKD) rats fed with the same diet as
Group 1, but containing 0.2% phosphate (¼CKD/0.2% Pi)
Within each treatment group, there were 16–18 animals initially
assigned to two different study durations: 34-week animals with
blood draws at 20, 29, and 34 weeks; 38-week animals with blood
draws at 20, 34, and 38 weeks. Rats were anesthetized with sodium
pentobarbital (50 mg/kg intraperitoneally) prior to killing and blood
was collected by cardiac puncture. After initial studies, a high
mortality rate was noted in the Group 2 animals and we added
additional animals to ensure adequate sampling for the vascular and
bone end points in each group. At the time of killing, half of the
animals from each study duration group were perfusion fixed with
4% paraformaldehyde in phosphate buffer to harvest tissue for bone
and aorta histology and the remaining animals from each study
duration group were saline perfused to harvest the thoracic aorta to
determine calcium content. If animals in the 38-week end point
required euthanasia or died after 25 weeks, they were replaced.
Plasma biochemistries. BUN, calcium, phosphorus, and
creatinine were determined using colorimetric assays (Pointe
Scientific, Canton, MI or Sigma, St Louis, MO, kits). Intact PTH
was determined by ELISA (Alpco, SalemNH).
Bone histomorphometry. Tibiae were removed, cleaned of soft
tissue, and cut into proximal and distal segments. Segments were
fixed in 10% neutral buffered formalin, dehydrated in ethanol, and
processed undecalcified into methyl methacrylate. Frontal sections
(4mm thick) of the proximal segments were cut using a Leica
RM2165 microtome and stained with von Kossa-tetrachrome for
measurement of static bone parameters at  250 magnification
1.0 mm distal to the chondro-osseous junction using a semiauto-
matic image analysis system (Osteomeasure Histomorphometry
System; Osteometrics Inc., Atlanta, GA, USA).31 Results are
presented using standardized histomorphometry measures.32 To
examine cortical bone geometry, cross-sections of the distal
segments containing the tibial shaft immediately proximal to the
tibiofibular junction were taken using a wire saw (Histo-saw, DDM
Table 4 | Comparison of impact of diets in 20-week animals
Cy/+ CKD animals
Casein (n=15) Grain (n=9) P-value
Serum
Calcium (mg/100 ml) 9.6±0.4 8.8±0.3 NS
Phosphorus (mg/100 ml) 5.4±0.2 5.4±0.3 NS
Intact PTH (pg/ml) (median 25/75%) 469±87 347±56 NS
FGF23 (pg/ml) (median 25/75%) 1254 (1183–1411) 869 (799–903) o0.001
Urine
FE phosphorus (%) (median 25/75%) 80.1 (67.2–116.7 24.2 (21.0–49.3) o0.001
Phosphorus (mg/24 h) (median 25/75%) 76.3 (58.3–87.8) 44.3 (39.4–49.0) o0.001
Calcium/creatinine ratio (mg/mg) 0.21±0.02 0.12±0.02 0.013
Calcium (mg/24 h) 3.2±1.1 2.9±1.2 NS
Stool
Calcium (mg/24 h) 49.7 (38.9–44.8) 74.0 (54.3–78.7) NS
Phosphate (mg/24 h) 33.1 (18.4–44.8) 30.6 (12.4–44.3) NS
CKD, chronic kidney disease; FE, fractional excretion; NS, not significant; PTH, parathyroid hormone.
Mean±s.e.m. unless otherwise indicated.
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P216) and mounted unstained. Total cross-sectional area was
measured from these sections using a Bioquant image analysis
system.
To quantify calcification, thoracic aortas from the saline-perfused
killed animals were snap frozen. At thawing, they were dried,
weighed, and then incubated in 0.6 N HCl for 48 h. The sample was
homogenized, centrifuged, and the supernatant analyzed for calcium
using the o-cresolphthalein complex one method (Calcium kit;
Pointe Scientific). For histology, thoracic aorta from the parafor-
maldehyde-perfused animals were placed in 4% paraformaldehyde,
then embedded in paraffin, sectioned, and stained with MacNeal’s
tetrachrome stain (a combination of von Kossa stain and toluidine
blue).33 The proximal thoracic aorta was used and 4–6 sections per
animal analyzed. The sections were graded semiquantitatively with
0¼ no calcification, 1þ ¼ small spots of calcification, 2þ ¼ single
area of calcification that spanned several cells and easily visualized
by low power, 3þ multiple areas of calcification. In one animal, the
aorta was processed for scanning electron microscopy. After the rat
was perfusion fixed, a segment of aorta with calcifications was
removed, rinsed, dehydrated in a graded series of ethanol and
critical-point dried. The tissue was attached to a carbon planchet
with carbon dag and carbon coated in a vacuum evaporator. The
specimen was analyzed using scanning electron microscopic back-
scattered imaging with a JEOL 8900 (JEOL USA Inc., Peabody, MA,
USA) equipped with an energy-dispersive spectrometer. Adjacent
calcified and non-calcified regions within the same specimen were
analyzed for differences in elemental content of the calcified lesions.
Diet study
After our initial results with the main study using the casein diet
revealed that the magnitude of hyperphosphatemia and hyperpar-
athyroidism was much more severe than our initial observations in
animals fed a predominantly grain-based diet, we added a fourth
treatment group of Cy/þ animals, which were fed a commercially
available grain diet (Purina 5002) composed of 20.7% protein, 0.6%
phosphorus, 0.8% calcium to evaluate the effects of casein versus
grain-based diets. These animals were similarly treated as detailed
above in the main study. The phytate content of the grain and
casein-based diets were analyzed by the ferric precipitate method.34
Metabolic cage study
To further examine the differences between phosphate homeostasis
in animals fed a casein diet versus a grain diet, we performed
additional metabolic studies. Twenty-week-old Cy/þ rats were fed
either the grain (Purina 5002 diet: 20% protein, 0.6% phosphate,
0.8% calcium, 4.5% fat)-based or the casein (Harlan Teklan
TD.04539 diet: 18% protein, 0.7% phosphorus, 0.7% calcium, 5%
fat)-based diets used in the main study. On day 6, animals were
placed into metabolic cages and urine and feces collected for
24 h. Animals were then killed and blood was collected. Blood
plasma was similarly analyzed for BUN, intact PTH, creatinine,
calcium, and phosphorus as described above. In addition, blood was
analyzed for FGF23 using an intact ELISA according to the
manufacturer’s protocol (Kainos Laboratories International, Tokyo,
Japan). This assay uses monoclonal antibodies and has been shown
to recognize full-length rodent FGF23.35 Urine was analyzed for
creatinine, calcium, and phosphorus using the colorimetric methods
described above. Feces were dried at 80 1C for 48 h, weighed,
ground, and then incubated with HCl for 96 h and analyzed
for calcium and phosphorus using the colorimetric methods
described above.
Statistical analyses
As noted above, multiple animals in Group 2 died or were killed and
additional animals added to ensure adequate numbers at end point.
All of the available data from all animals were utilized in an
‘intention to treat’ analysis, such that there were more samples for
the 20-week blood draw than the final blood draw. Thus, the actual
sample size for each of the measures ranges from group-to-group
and is provided in the Results section. If animals were killed before
being profoundly moribund, the final blood draw was utilized and
the actual time of the blood draw for all samples utilized in the
mixed models. For the main study, comparisons between the
different animal groups (Groups 1–3) were made by using regression
models adjusting for potential confounding variables. For outcomes
that were measured at three time points (PTH, calcium, phos-
phorus, weight), a mixed model repeated-measures analysis was
used to examine comparisons between the animal groups, adjusting
for the baseline value of the outcome. For the outcomes that were
measured twice (at baseline and end point¼BUN), an ANOVA
model adjusting for the baseline value of the outcome was used to
predict the differences in the outcome between the animal groups.
For the outcomes measured once (Hematocrit, bone histomorpho-
metry, and aorta calcium content in the main study, and results for
the metabolic studies), we used ANOVA with adjustment for
multiple comparisons or Pearson Product to compare biochemical
calcification to biochemical data. The results are presented as
mean±s.e.m. (for normally distributed variables), or median with
25/75% (for non-normally distributed variables).
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